The acquisition of the European commercial rights to Stelara could boost the Hungarian pharmaceutical company Richter’s sales by EUR 100 million a year if the European Medicines Agency (EMA) approves the drug in the near future, analysts at Erste have calculated.
The Hungarian company announced yesterday that it has been granted exclusive commercial rights to the biosimilar Stelara under a contract with Chinese firm Bio-Thera Solutions, writes Világgazdaság.
Fact
A biosimilar is a biological medicinal product that is highly similar to another biological medicinal product that is already authorized. Biosimilar medicinal products are approved according to the standards for pharmaceutical quality, safety, and efficacy that apply to all biological medicinal products. The European Medicines Agency (EMA) is responsible for assessing the majority of marketing applications for biosimilar medicines in the European Union (EU).
The drug, developed by a Chinese sector partner for the treatment of Crohn’s disease, ulcerative colitis, …